Medicines for Malaria Venture (MMV) is a leading product development partnership (PDP) in the field of antimalarial drug research and development. Its mission is to reduce the burden of malaria in disease-endemic countries by discovering, developing and delivering new, effective and affordable antimalarial drugs.
Over the past two decades, MMV has worked with an extensive network of donors, private and public sector partners, experts and clinical centers in endemic countries to develop an outstanding portfolio of antimalarial projects.
Our portfolio is financed through funding support coming from government agencies, private and corporate foundations, international organizations, corporations and private individuals. MMV is fortunate to have a solid standing, with a healthy strategy already set for our resource mobilization in 2026 and beyond
For a newly created position we are currently seeking a Senior Director for Philanthropic Partnerships who will form a footprint in our success and play a critical role in driving MMV’s next generation of funding growth. The Senior Director will lead on cultivating bold, high-value philanthropic and innovative financing partnerships with a focus on diversifying MMV’s donor base, catalysing new sources of investment, and expanding MMV’s reach within the broader philanthropic and private capital ecosystem. This role is not just about identifying prospects, it’s about conceptualising and implementing entry points, telling MMV’s story in new and resonant ways, and helping shape the organisation’s positioning in a shifting global health financing environment. It requires creativity, influence, discipline, and deep familiarity with philanthropic motivations and trends.
The Senior Director will provide daily leadership to MMV’s new revenue work across philanthropic donors, working closely with the Head of Resource Mobilisation, and will actively contribute to the development of MMV’s long-term funding strategy
Duties and Responsibilities
Success metrics
Education and Experience:
Technical Skills:
Behavioural Skills:
Starting date: earliest start date possible
Interested applicants should send their CV and a cover letter giving reasons for their intere st in the position before Wednesday 23 October 2025. During the interview process, we will ask you to provide details about the types of funding sources you are connected with and the geographic locations of those networks.
We consider individuals for employment based on their skills, abilities and experience. We thrive to attract and hire a strong, talented and diverse workforce, prohibiting discrimination based on race, colour, religious or political beliefs, age, nationality, physical, mental or developmental disability, gender, sexual orientation.
MMV’s offices are located in Geneva, Switzerland, where we work in a hybrid workplace environment. We would expect the selected candidate to be at the office at least 40% of their desk working time. This is not a remote hire and MMV offers relocation assistance for suitable qualified candidates coming from abroad.
For more information about MMV’s activities please refer to our website www.mmv.org.
Recruitment agencies are kindly requested to refrain from submitting applications.
Medicines for Malaria Venture (MMV) is a leading product development partnership (PDP) in the field of antimalarial drug research and development. Its mission is to reduce the burden of malaria in disease-endemic countries by discovering, developing and delivering new, effective and affordable antimalarial drugs.
Over the past two decades, MMV has worked with an extensive network of donors, private and public sector partners, experts and clinical centers in endemic countries to develop an outstanding portfolio of antimalarial projects.
Our portfolio is financed through funding support coming from government agencies, private and corporate foundations, international organizations, corporations and private individuals. MMV is fortunate to have a solid standing, with a healthy strategy already set for our resource mobilization in 2026 and beyond